A UK-based oncology drug development company sought to understand the potential value of a small molecule product in metastatic breast cancer (MBC). Alacrita was commissioned to produce an independent sales forecast to help the client understand the potential value of the product in three separate therapy lines.
Alacrita performed an extensive review of the literature and of its pharma databases to validate MBC as a target indication given the product mechanism. We then estimated the current and projected target patient population and, having gained an understanding of the therapeutic landscape, we estimated market share in each line of therapy. Using benchmark products to estimate pricing and likely timelines to approval, we created a sales forecast and an accompanying PowerPoint report describing our analysis and assumptions.
We can help you gauge and rank the opportunities for your R&D programs or technology platforms to deliver value, by framing the commercial potential and charting the path to market.